Medivation, OncoFusion Therapeutics deal

OncoFusion granted Medivation access to OncoFusion's preclinical library of small molecule inhibitors of the BET bromodomain family. Medivation will have exclusive, worldwide rights to develop and commercialize selected compounds. OncoFusion is eligible to receive undisclosed upfront payments and milestones, plus royalties. The partners could not be reached for details.

In a paper published in Nature this month, a BET bromodomain inhibitor significantly reduced tumor volume and weight vs. Xtandi enzalutamide in a mouse model of metastatic castration-resistant prostate cancer (CRPC). OncoFusion co-founder Arul Chinnaiyan is corresponding author of the article. ...